High affinity VEGF binder could be CNV treatment of the future

Article

A single intravitreal injection of the fusion protein KH902 can effectively inhibit leakage and growth of choroidal neovascularization in rhesus monkeys.

A single intravitreal injection of the fusion protein KH902 can effectively inhibit leakage and growth of choroidal neovascularization (CNV) in rhesus monkeys, according to a study published online by Molecular Vision.

Ming Zhang from Sichuan University and fellow researchers from Chengdu Kanghong Biotechnology, Sichuan Province, China measured the binding affinity of KH902 with vascular endothelial growth factor (VEGF) by using the human VEGF ELISA kit. The biological activity effect of KH902 was assayed by an in vitro inhibition experiment on human umbilical vein endothelial cell proliferation that was induced by VEGF. The experimental CNV was induced by causing perimacular laser injury in the eyes of rhesus monkeys and confirmed by fluorescence fundus angiography (FFA), optical coherence tomography (OCT) and multifocal electroretinograms (mf-ERG) 20 days following the infliction of the laser injury.

KH902 was delivered to the animals through intravitreal injection at various doses and the monkeys were observed four-weeks following the injection by ophthalmic injection, FFA, OCT, mf-ERG, histopathology and immunohistochemistry analysis.

Overall, the team found that KH902 binds VEGF with high affinity and hence can completely block VEGF-induced cell proliferation and cell growth.

The reduction of experimental CNV was greater in eyes treated with 300 and 500 µg than in eyes treated with 0.1 mg KH902. In eyes treated with 100 µg, there was fibre-vasculosa membrane proliferation, but not in the 300 and 500 µg groups. The results of mf-ERG demonstrated that there was a greater improvement in the 300 and 500 µg groups than in the 100 µg group.

The researchers believe that, since KH902 can effectively inhibit leakage and growth of CNV, it may have uses in the future as an anti-angiogenic treatment for age-related macular degeneration.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.